286 related articles for article (PubMed ID: 26220282)
21. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
Ogata N; Ichida T; Aoyagi Y; Kitajima I
Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L.
Liu S; Wei W; Shi K; Cao X; Zhou M; Liu Z
J Ethnopharmacol; 2014 Sep; 155(2):1061-7. PubMed ID: 25009077
[TBL] [Abstract][Full Text] [Related]
23. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
24. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
Warner N; Locarnini S; Kuiper M; Bartholomeusz A; Ayres A; Yuen L; Shaw T
Antimicrob Agents Chemother; 2007 Jul; 51(7):2285-92. PubMed ID: 17438047
[TBL] [Abstract][Full Text] [Related]
25. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
26. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
27. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A
J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo anti-hepatitis B virus activities of the lignan nirtetralin B isolated from Phyllanthus niruri L.
Liu S; Wei W; Li Y; Lin X; Shi K; Cao X; Zhou M
J Ethnopharmacol; 2014 Nov; 157():62-8. PubMed ID: 25260580
[TBL] [Abstract][Full Text] [Related]
29. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
30. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
31. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
[TBL] [Abstract][Full Text] [Related]
32. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
33. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
34. Application of allele-specific RNAi in hepatitis B virus lamivudine resistance.
Teng X; Liu JY; Li D; Fang Y; Wang XY; Ma YX; Chen SJ; Zhao YX; Xu WZ; Gu HX
J Viral Hepat; 2011 Oct; 18(10):e491-8. PubMed ID: 21914068
[TBL] [Abstract][Full Text] [Related]
35. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
36. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
[TBL] [Abstract][Full Text] [Related]
37. A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.
Kiruthika S; Bhat R; Jayaram B; Vivekanandan P
J Antimicrob Chemother; 2022 Jul; 77(8):2120-2124. PubMed ID: 35514268
[TBL] [Abstract][Full Text] [Related]
38. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
39. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.
Torresi J
J Clin Virol; 2002 Aug; 25(2):97-106. PubMed ID: 12367644
[TBL] [Abstract][Full Text] [Related]
40. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Cho YK; Cui XJ; Jeong SU; Song BC
Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]